No 13F manager has reported this stock in the last 8 quarters.
None.
None.
No insider has filed a notice of proposed sale (Form 144) for Obsidian Therapeutics, Inc. in the last 12 months.
No 13F manager reports holding OBX.
| Fund | Position value | Shares | % of company | % of the fund | As of |
|---|---|---|---|---|---|
|
FN
Fidelity Concord Street Trust
|
$27.2K | 1.6K | 0.00% | 0.00% | August 31, 2026 |
| Holder | Shares | % of company | Change vs last qtr | 8 quarters | Held since | % of their book |
|---|---|---|---|---|---|---|
|
NM
Norkunas Matthew
Insider
|
30.9K | 0.08% | — | — |
— | — |
|
Insider holdings come from Form 3/4/5 filings, which are not quarterly.
Share of the company0.080%
|
||||||
Loading...